MedTrace Logo

Cholera Vaccine Investment Strategy in Bangladesh

NCT02727855 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75170

Last updated 2019-12-20

No results posted yet for this study

Summary

To evaluate the preventive impact, demand, acceptability, uptake, feasibility, and cost-effectiveness of a two-dose regimen of the OCV Shanchol in children living in urban slums in Bangladesh, Investigators will conduct a targeted mass immunization programme, using an innovative approach successfully deployed by the Bangladesh government in its recent countrywide campaign of MR vaccination of 52 million children aged 9 months to 14 years (\<15 years). Investigators will undertake a census of a geographic population of approximately 300,000 persons, with GIS locations of each household. This census will be updated every 6 months during the follow-up period to permit tracking of births, deaths, and migrations, including changes in location of each individual's residence. Following the initial census, the OCV will be offered to all non-pregnant individuals aged 1 to 14 years. Operational research and economic studies will evaluate the coverage, feasibility, acceptability, demand, costs and cost-effectiveness of this vaccination programme.

Conditions

  • Cholera

Interventions

BIOLOGICAL

Shanchol

Oral Cholera Vaccine

Sponsors & Collaborators

  • Gavi, The Vaccine Alliance

    collaborator OTHER

  • Government of Bangladesh

    collaborator OTHER_GOV

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    lead OTHER

Principal Investigators

  • Dr. Firdausi Qadri, PhD · International Centre for Diarrhoeal Disease Research, Bangladesh

Eligibility

Min Age
1 Year
Max Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727855 on ClinicalTrials.gov